2023 World Conference on Lung Cancer (Posters)-P2.08. EDGE-Lung: A Phase 2 Open-Label Platform Study to Evaluate Immunotherapy-Based Combinations in Patients with Metastatic NSCLC

P2.08. EDGE-Lung: A Phase 2 Open-Label Platform Study to Evaluate Immunotherapy-Based Combinations in Patients with Metastatic NSCLC - PDF(Abstract)

Back to course

Pdf Summary

The EDGE-Lung study is a phase 2 trial that aims to evaluate the safety and effectiveness of novel treatment combinations for metastatic non-small cell lung cancer (NSCLC). Despite advances in PD-[L]1 inhibition, there is a need for improved treatment options. The study will investigate the use of quemliclustat (quemli), a CD73 inhibitor that reduces immunosuppressive adenosine, domvanalimab (dom), a TIGIT inhibitor that promotes antitumor activity, and zimberelimab (zim), a PD-1 inhibitor that increases immune-mediated tumor cell death.<br /><br />The study is a multicenter, randomized, open-label trial that includes different population sub-studies. In substudy A, treatment-naive patients with metastatic PD-L1-high NSCLC will receive either quemli or dom in combination with zim. In substudy B, treatment-naive, PD-L1 all-comer patients with metastatic NSCLC will receive either quemli, dom, or both, in combination with zim and platinum doublet chemotherapy. In substudy C, patients who have progressed after prior treatment will receive docetaxel in combination with either quemli or dom in combination with zim.<br /><br />The primary endpoints of the study are objective response rate and safety. Other endpoints include disease control rate, progression-free survival, duration of response, overall survival, and pharmacokinetics. The study is enrolling patients in Asia-Pacific, Europe, and North America.<br /><br />The study aims to evaluate the clinical activity and safety of novel treatment combinations for metastatic NSCLC. By targeting CD73, TIGIT, and PD-1, the study hopes to improve long-term outcomes for patients with advanced NSCLC. The findings of this study could potentially lead to the development of new treatment options for patients with metastatic NSCLC.

Asset Subtitle

Melissa Johnson

Meta Tag

Speaker Melissa Johnson

Topic Metastatic NSCLC: Immunotherapy - TIPs

Keywords

EDGE-Lung study

phase 2 trial

metastatic non-small cell lung cancer

NSCLC

quemliclustat

CD73 inhibitor

domvanalimab

TIGIT inhibitor

zimberelimab

PD-1 inhibitor